跳至主要内容
临床试验/NCT01918904
NCT01918904撤回2 期

A Pilot Study to Evaluate Topical Sodium Thiosulfate Therapy for Calcinosis Cutis (STS-CALC)

Loyola University0 个研究点开始时间: 2013年9月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
撤回
发起方
主要终点
Change in calcinosis cutis lesion size from week 0 to week 12 for the experimental arm versus placebo arm

研究概览

简要总结

Calcinosis cutis refers to a group of disorders characterized by calcium deposition in the skin (1). The disorders are classified according to etiology into the following types: dystrophic, metastatic, iatrogenic, and idiopathic (1,2). Dystrophic calcification occurs in the setting of varicosities, infection, tumors, and connective tissue disorders (1). The connective tissue disorders most commonly associated with calcinosis cutis are systemic sclerosis and dermatomyositis, although it has also been reported in patients with systemic lupus erythematosus, undifferentiated connective tissue disorder, and mixed connective tissue disorder (2). The pathophysiology of calcinosis cutis is not well understood, and there is a broad range of severity seen, from benign localized, small nodules to large, severely debilitating lesions (2). Although many therapies have been investigated for treatment of calcinosis cutis, including calcium channel blockers, colchicine, minocycline, intravenous immunoglobulin, and bisphosphonates, results have been mixed at best (2). Surgical removal is sometimes feasible in the case of a localized lesion, however, recurrence after surgery is common (2).

Recently, several authors have reported cases of dramatic resolution of dystrophic calcinosis cutis lesions with topical sodium thiosulfate preparations (1,3,4). Systemic sodium thiosulfate therapy is commonly used to treat calciphylaxis in patients with renal disorders with very few adverse events (1). A search of the literature to date yields no formal studies that aim to determine whether topical sodium thiosulfate is truly an effective therapy for calcinosis cutis. As a result, patients are often treated with therapies that are unproven or ineffective and their calcinosis cutis eventually leads to significant pain and disability.

Research Question:

Does treatment of dystrophic calcinosis cutis with topical sodium thiosulfate result in diminution of the lesion and associated pain?

Objective:

The objective of this pilot study is to investigate whether topical sodium thiosulfate is an effective therapy for calcinosis cutis. This study will also determine the feasibility of our protocol and provide information to help direct a future full-scale trial.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients seen by the Division of Rheumatology at Loyola Outpatient Center in Maywood, Illinois (IL), Oak Brook Terrace Outpatient Center in Oakbrook, IL, and Burr Ridge Outpatient Center in Burr Ridge, IL.
  • Male and female patients 18 years old and above
  • Patients with at least 2 distinct calcinosis cutis lesions separated by at least 10 inches, that are a minimum of 2 millimeters (mm) in diameter, and identifiable on physical exam and ultrasound, such that one lesion may be used as an internal control lesion
  • Patients on calcium channel blockers, bisphosphonates, prednisone, and colchicine will be included

排除标准

  • Patients with calcinosis cutis lesions that appear actively infected (i.e., exhibiting purulent drainage and malodor) will not be included
  • Patient with concomitant use of systemic intravenous sodium thiosulfate for treatment of calciphylaxis will not be included
  • Patients with hypercalcemia will not be included
  • Patients who are pregnant or breastfeeding will not be included
  • Patients who are allergic to sulfa and/or zinc will not be included

研究组 & 干预措施

Sodium Thiosulfate

Experimental

A small amount of 25% topical sodium thiosulfate cream twice daily (bid)

干预措施: Sodium thiosulfate (Drug)

Placebo

Placebo Comparator

A small amount of topical zinc oxide and aquaphor cream twice daily (bid)

干预措施: Placebo (Drug)

结局指标

主要结局

Change in calcinosis cutis lesion size from week 0 to week 12 for the experimental arm versus placebo arm

时间窗: After 12 weeks of treatment

Definition: Calcinosis cutis lesion. Change Calculation Details: The lesion size will be evaluated at week 0 and again at week 12. Continuous measurement of the lesion in millimeters (mm), where a decrease in diameter indicates improvement.

次要结局

  • Change in pain from week 0 to week 12 for the experimental arm versus placebo arm(After 12 weeks of treatment)
  • Change in pain from week 0 to week 24 for the experimental arm versus placebo arm(After 24 weeks of treatment)
  • Change in calcinosis cutis lesion size from week 0 to week 24 for the experimental arm versus placebo arm(After 24 weeks of treatment)

研究者

发起方
Loyola University
申办方类型
Other
责任方
Principal Investigator
主要研究者

Elaine Adams

Professor

Loyola University

相似试验